Discrete Particles In Supporting Matrix Patents (Class 424/469)
  • Patent number: 8865213
    Abstract: Disclosed herein are multiparticulate modified release pharmaceutical compositions comprising: (a) a first portion comprising an active ingredient, at least one surfactant and at least one release modifying agent and (b) a second portion comprising an active ingredient and optionally a release modifying agent. Particularly, the active ingredient in the first portion is a calcium channel blocker and the modified release composition is in the form of a multiparticulate tablet.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: October 21, 2014
    Assignees: USV Limited, Indicus Pharma LLC
    Inventors: Nitin Vadilal Sheth, Sunil Suresh Jog, Santosh Sadashiv Chothe, Sampada Hemant Tupe
  • Patent number: 8865219
    Abstract: The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO?), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: October 21, 2014
    Assignee: Ethypharm
    Inventors: Mahendra B. Chaudhari, Edouard Gendrot
  • Patent number: 8865214
    Abstract: Bioactive formulations and methods of use comprising a gypsum biopolymer matrix and soil beneficial microorganisms are described herein.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: October 21, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Syed H. Imam, Gregory M. Glenn, Farooqe Azam
  • Patent number: 8858995
    Abstract: Compositions are provided that comprises a biocompatible polymeric matrix incorporating an effective amount of a phytochemical agent, a combination of phytochemical agents, or a phytochemical agent and one or more additional therapeutic agents. Methods of treating a cancer using the compositions are further provided.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: October 14, 2014
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Ramesh C. Gupta, Manicka V. Vadhanam, Farrukh Aqil
  • Patent number: 8852626
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: October 7, 2014
    Assignees: Otonomy, Inc., The Regents of the University of California
    Inventors: Jay Lichter, Carl Lebel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Andrew M. Trammel, Jeffrey P. Harris
  • Patent number: 8846085
    Abstract: A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m2/g, and c) 0-40% by weight of further excipients, with the proviso that the total amount of components a) to c) corresponds to 100% by weight, where at least 50% of the surface of the ibuprofen crystals are covered with the finely divided excipient.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: September 30, 2014
    Assignee: BASF SE
    Inventors: Kathrin Meyer-Boehm, Karl Kolter, Anisul Quadir
  • Patent number: 8840925
    Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: September 23, 2014
    Assignee: Aptalis Pharmatech, Inc.
    Inventors: Gopi M. Venkatesh, Nehal H. Vyas, Michael Gosselin, Jin-Wang Lai
  • Patent number: 8840923
    Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: September 23, 2014
    Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
    Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
  • Patent number: 8840924
    Abstract: The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin; and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: September 23, 2014
    Assignee: NEOS Therapeutics, LP
    Inventors: Mark Tengler, Russell McMahen
  • Patent number: 8828432
    Abstract: Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biologically, or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The additional component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass.
    Type: Grant
    Filed: February 13, 2001
    Date of Patent: September 9, 2014
    Assignee: General Mills, Inc.
    Inventor: Bernhard H. van Lengerich
  • Patent number: 8828431
    Abstract: The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: September 9, 2014
    Assignee: Merrion Research III Limited
    Inventors: Kenneth Iain Cumming, Zebunnissa Ramtoola
  • Publication number: 20140242162
    Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.
    Type: Application
    Filed: October 3, 2012
    Publication date: August 28, 2014
    Inventors: Anke Diederich, Kurt Liechti, Peter Kuehl, Wing Cheung
  • Patent number: 8815293
    Abstract: A depot formulation comprising iloperidone and a biodegradable, biocompatible polymer. Preferably, the polymer is a star polymer.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: August 26, 2014
    Assignee: Novartis AG
    Inventors: Markus Ahlheim, Rolf Loeffler
  • Patent number: 8815287
    Abstract: Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: August 26, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Christopher Breder, Curtis Wright, Benjamin Oshlack
  • Patent number: 8808740
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: August 19, 2014
    Assignee: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • Patent number: 8795723
    Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: August 5, 2014
    Assignee: Angelini Pharma Inc.
    Inventors: Sonia Gervais, Damon Smith, Pauline Contamin, Rachid Ouzerourou, My Linh Ma
  • Patent number: 8795726
    Abstract: The present invention provides compositions for extended release of a nucleic acid agent, a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: August 5, 2014
    Assignee: Polypid Ltd.
    Inventors: Noam Emanuel, Yosef Rosenfeld
  • Patent number: 8784870
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: July 22, 2014
    Assignees: Otonomy, Inc., The Regents of the University of California
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Patent number: 8784888
    Abstract: Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 22, 2014
    Assignee: Cosmo Technologies Limited
    Inventors: Roberto Villa, Massimo Pedrani, Mauro Ajani, Lorenzo Fossati
  • Patent number: 8778395
    Abstract: A controlled release diltiazem dosage formulation comprising a plurality of diltiazem pellets and a gel-forming material where the time of maximum diltiazem blood plasma levels occurs more than 8 hours after administration and preferably more than 10 hours after administration.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: July 15, 2014
    Assignee: Andrx Labs, LLC
    Inventors: Xiu Xiu Cheng, Xiaohong Qi, Guohua Zhang, Manesh Dixit
  • Patent number: 8778396
    Abstract: This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: July 15, 2014
    Assignee: University of the Witwatersrand, Johannesburg
    Inventors: Viness Pillay, Yahya Choonara, Caragh Murphy, Sarashnee Moonisami
  • Patent number: 8747895
    Abstract: A coated multi-particulate pharmaceutical dosage form such as an orally disintegrating tablet (ODT) presentation for delivering atomoxetine or a pharmaceutically acceptable salt thereof, a selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD, into the body to maintain a therapeutically effective amount of atomoxetine in the plasm. The dosage form may comprise one or more populations of coated atomoxetine-containing particles (beads, pellets, granules etc.) providing a pre-designed rapid release profile after a predesigned lag-time of about 0 to 6 hours following oral administration.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: June 10, 2014
    Assignee: Aptalis Pharmatech, Inc.
    Inventors: Gopi M. Venkatesh, Troy M. Harmon, John Taylor
  • Patent number: 8722090
    Abstract: The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: May 13, 2014
    Assignee: Hexal AG
    Inventors: Karin Klokkers, Ina Elfriede Otto, Heidemarie Edith Elfriede Meyer
  • Patent number: 8703191
    Abstract: Controlled-release tablets exhibiting excellent storage stability are achieved by granulating a pharmaceutically active agent with a hydroxyalkylcelluose, blending the resulting granules with an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which may be optionally coated, such as with an enteric coating composition, to provide delayed release and/or to enhance stability of the active agent.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: April 22, 2014
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement
  • Patent number: 8703189
    Abstract: The present invention provides a medicinal composition that exhibits excellent storage stability and, even over long-term storage, little change in the release rate of the pharmacologically active substance contained therein. The medicinal composition of the invention prepared by dissolving or dispersing a pharmacologically active substance and a pH-independent water-insoluble polymer in a molten low-melting substance, and which can be prepared by spraying a liquid substance, obtained by dissolving or dispersing the pharmacologically active substance in a molten mixture comprising the low-melting substance and the pH-independent water-insoluble polymer, and then cooling the liquid substance.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: April 22, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Yuso Tomohira
  • Patent number: 8691270
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 8, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8685447
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 1, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8685443
    Abstract: A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: April 1, 2014
    Assignee: Alpharma Pharmaceuticals LLC
    Inventor: Garth Boehm
  • Patent number: 8679535
    Abstract: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: March 25, 2014
    Assignee: Endo Pharmaceuticals Inc.
    Inventors: Anand R. Baichwal, Troy W. McCall, Lirong Liu, Steve Labudzinski
  • Patent number: 8673344
    Abstract: The present invention relates to a solid dosage form with at least one film, which contains an active substance at least in sections, and the concentration of the active substance in the film or in the films has a gradient in a direction normal to the thickness of film. The invention further relates to a method of producing a solid dosage form, in which at least one film is produced, containing an active substance at least in sections, with the concentration of the active substance having a gradient in the longitudinal direction of the film.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: March 18, 2014
    Assignee: Abbvie Deutschland GmbH & Co. KG
    Inventors: Jörg Rosenberg, Jörg Breitenbach, Peter Heilmann, Helmuth Steininger
  • Patent number: 8668932
    Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: March 11, 2014
    Assignee: Andrx Pharmaceuticals, LLC
    Inventors: Manesh Dixit, Xiu-Xiu Cheng, Avinash Nangia, Chin Ming Chen
  • Patent number: 8668934
    Abstract: A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: March 11, 2014
    Assignee: Novartis AG
    Inventors: Reinhard Vehring, Danforth P Miller, David Lechuga-Ballesteros
  • Patent number: 8668929
    Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: March 11, 2014
    Assignee: Depomed, Inc.
    Inventors: Chien-Hsuan Han, Sui Yuen Eddie Hou, Monica L. Reid
  • Patent number: 8647656
    Abstract: The compositions of the present invention composition comprise a therapeutically effective amount of particles comprising lamotrigine, in combination with granules comprising a disintegrant, and a sugar alcohol and/or a saccharide. These compositions are useful in treating epilepsy and bipolar disorder, particularly for patients with dysphagia, and to improve compliance with bipolar patients.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: February 11, 2014
    Assignee: Aptalis Pharmatech, Inc.
    Inventors: Gopi M. Venkatesh, Nehal H. Vyas, Michael Gosselin, Jin-Wang Lai
  • Patent number: 8642082
    Abstract: Pharmaceutical compositions suitable for the oral administration of heparin or derivatives thereof, particularly controlled-release oral pharmaceutical compositions containing heparin with different molecular weight, for the treatment of inflammatory bowel diseases and related conditions, are disclosed.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: February 4, 2014
    Assignee: Cosmo Technologies Limited
    Inventors: Mauro Ajani, Luigi Moro, Roberto Villa
  • Patent number: 8637079
    Abstract: A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: January 28, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura
  • Patent number: 8632805
    Abstract: The present invention includes a controlled-release composition having a matrix. The matrix contains a pharmaceutically effective amount of an active agent or a pharmaceutically acceptable salt, solvate, ester, and/or prodrug thereof, an ionic non-gelling matrix polymer, and a pH modifier. The ionic non-gelling matrix polymer is practically insoluble and unswellable at a first aqueous fluid pH and is soluble at a second aqueous fluid pH. The pH modifier is present in an amount to control the release of the active agent from the composition. The controlled-release composition is substantially free of a gelling or swellable excipient. The present invention also provides methods of making and using the controlled-release compositions.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: January 21, 2014
    Assignee: Mutual Pharmaceutical Company, Inc.
    Inventors: Gandha V. Naringrekar, Kristin A. Arnold, David Erkoboni
  • Publication number: 20140010875
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Application
    Filed: September 11, 2013
    Publication date: January 9, 2014
    Applicant: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • Patent number: 8617596
    Abstract: A process is provided for efficiently producing sustained-release tablets having superior sustained-release properties capable of inhibiting the initial elution of a drug and allowing the drug to be completely eluted after a prescribed amount of time has elapsed. A process for producing sustained-release tablets comprising: dry granulating a mixture composed of a hydroxyalkyl cellulose (A) having a viscosity of 1 to 50 mPa·s in a 2% by mass aqueous solution at 20° C., a hydroxyalkyl cellulose (B) having a viscosity of 100 mPa·s or more in a 2% by mass aqueous solution at 20° C., an active ingredient and an additive, and forming the resulting granules into tablets.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: December 31, 2013
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Takeshi Honma, Kenji Furukawa
  • Patent number: 8617587
    Abstract: The present invention relates to the supply and production of an animal medicine consisting of a substrate in pellet or tablet form, which is attractive to livestock and domestic animals, in which fine-grained particles of a neutral-tasting, physiologically compatible, solid carrier material are embedded, which is characterized in that said fine-grained particles of carrier material have an average diameter of 0.09 to 0.8 mm and are coated with an active substance from veterinary medicine, and said active substance layer is covered with a protective layer of a physiologically compatible polymer matrix, and to the production of this animal medicine. It also relates to the usage of said double-coated, fine-grained particles of carrier material in the production of a preparation for veterinary medicine.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: December 31, 2013
    Assignee: Novartis AG
    Inventors: Hubert Thoma, Uwe Thomas Schote, Ute Isele
  • Patent number: 8603524
    Abstract: A composition including an ethylene blocking agent complex formed from the product of an ethylene blocking agent and a host, and at least one water-soluble polymer, wherein the ethylene blocking agent complex and the at least one water-soluble polymer are intermingled is disclosed.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: December 10, 2013
    Assignee: Dow AgroSciences LLC
    Inventors: Gretchen Baier, Mark D. Newsham, Irina V. Graf, Robert L. Schmitt, Lamy J. Chopin, III, Jacquelyn A. Degroot, Jeffrey J. Wooster, Tarlochan S. Dhadialla
  • Patent number: 8603525
    Abstract: An orally disintegrating multilayer tablet comprising at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and a pore-forming agent.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: December 10, 2013
    Assignee: Ethypharm
    Inventors: Pascal Oury, Catherine Herry, Didier Hoarau
  • Patent number: 8592364
    Abstract: Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 26, 2013
    Assignee: Ecole Polytechnique Federale de Lausanne (“EPFL”)
    Inventors: Melody A. Swartz, Jeffrey A. Hubbell, Alice A. Tomei, Jacqueline D. Shields, Iraklis Kourtis
  • Patent number: 8591946
    Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: November 26, 2013
    Assignee: Veloxis Pharmaceuticals A/S
    Inventor: Per Holm
  • Patent number: 8568776
    Abstract: Enteric coated multiparticulate formulations that use L-menthol as an active ingredient are disclosed. In one embodiment, the multiparticulate formulation comprises a plurality of particulates having a reduced release under gastric conditions and an elevated release at neutral pH. The particulates comprise a core comprising L-menthol as an active ingredient. The L-menthol is supplied to the core as an at least 80% pure L-menthol material. An enteric coating is over the core. The enteric coating is effective to release at least about 80% of the L-menthol within about two hours of being placed in a substantially neutral pH environment. Other aspects of the invention include methods of making and methods of using the multiparticulate formulations.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: October 29, 2013
    Assignee: ZX Pharma, LLC
    Inventors: Syed M. Shah, Daniel Hassan, Sarah Hassan
  • Patent number: 8545889
    Abstract: The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the co-processed carbohydrate system, some of which, when placed in the oral cavity, shall dissolve or disintegrate, preferably within about 60 seconds.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: October 1, 2013
    Assignee: SPI Pharma, Inc.
    Inventors: Gary T. Norman, Kalyan S. Nuguru, Arun F. Amin, Sarath Chandar
  • Patent number: 8535716
    Abstract: A pharmaceutical composition is provided that includes an active ingredient in the form of a powder or granule, a water soluble high molecular weight excipient and a water insoluble hydrophilic amphiphilic excipient. These ingredients are solution mixed and dried to form a modified pharmaceutical ingredient in simultaneous contact with both the water soluble high molecular weight excipient and the water insoluble hydrophilic amphiphilic excipient. Adjuvants are compacted about the modified pharmaceutical ingredient as well as a release control agent. The release control agent being present at levels from 1 to 40 total weight percent of the pharmaceutical composition.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: September 17, 2013
    Assignee: TSRL, Inc.
    Inventors: John Hilfinger, Jae Seung Kim, Paul Kijek
  • Publication number: 20130224297
    Abstract: A solid oral pharmaceutical composition in the form of a tablet consisting of a core including a Krebs cycle precursor salt as active ingredient, and of a coating including a coating agent, the composition including from 40% to 80% by weight of this precursor salt on the basis of the total weight of the composition, the composition being able to release this salt in vitro, both in purified water at pH 7 and in a solution buffered at pH 1.3, with a dissolution device in accordance with the European Pharmacopoeia, at a rate of from 2 to 15% in 15 minutes, from 15 to 25% in 30 minutes, and from 30 to 50% in one hour. The composition is a usefeul medicament, in particular in the treatment and/or prevention of urinary lithiasis occurring at a physiological pH and/or during urinary acidosis and/or during hypocitraturia and/or during hypercalciuria and/or during hyperoxaluria.
    Type: Application
    Filed: November 18, 2011
    Publication date: August 29, 2013
    Applicant: Advicenne
    Inventors: Caroline Roussel-Maupetit, Luc-Andre Granier, Catherine Guittet
  • Patent number: 8506998
    Abstract: A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: August 13, 2013
    Assignee: Euro-Celtique S.A.
    Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Trevor John Knott, Hassan Mohammad
  • Patent number: RE44459
    Abstract: The invention disclosed comprises a method for administering the antidiabetic drug glipizide to a patient in need of glipizide in need of antidiabetic therapy.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: August 27, 2013
    Assignee: Alza Corporation
    Inventors: Anthony L. Kuczynski, Atul Devdatt Ayer, Patrick S. L. Wong